Of note, tovorafenib appears to have antitumor activity in the setting of BRAF alterations without the clinical manifestations of paradoxical activation seen with type I BRAF inhibitors, such as the development of cutaneous squamous cell carcinoma or keratoacanthoma. This evidence concerns the gene SGCG and cutaneous squamous cell carcinoma.